Stockreport

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

KemPharm, Inc.  (KMPH) 
Last kempharm, inc. earnings: 2/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kempharm.com/investor-overview
PDF APADAZ® Now Approved in Three Dosage Strengths, Providing Greater Flexibility to Prescribers Through Additional Dosing Options CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE [Read more]